NYSE · Healthcare
Mistras Group, Inc. (MG)
As-reported financials and recent SEC filings for Mistras Group, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$724.0M
Net income
$16.8M
Net margin
2.3%
Diluted EPS
$0.53
ROE
7.1%
P/E (TTM)
26.9×
Market cap
$598.8M
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $724.0M | $729.6M | $705.5M | $687.4M | $677.1M |
| Gross profit | — | — | — | — | — |
| Operating income | $40.6M | $39.8M | $-1.9M | $19.8M | $18.2M |
| Net income | $16.8M | $19.0M | $-17.5M | $6.5M | $3.9M |
| Diluted EPS | $0.53 | $0.60 | $-0.58 | $0.21 | $0.13 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
S-82026-06-18
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →SCHEDULE 13D/A2026-06-12
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →32026-06-04
View on EDGAR →SCHEDULE 13D/A2026-06-04
View on EDGAR →Go deeper on MG
Search Mistras Group, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.